期刊
EXPERIMENTAL AND MOLECULAR MEDICINE
卷 51, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s12276-019-0339-7
关键词
-
资金
- 'KRIBB Research Initiative Program' by the Ministry of Science and ICT [NRF-2016M3A9B6903343]
- 'Bio & Medical Technology Development Program' by the Ministry of Science and ICT [NRF-2016M3A9B6903343]
- 'R&D Convergence Program of the National Research Council of Science Technology [CAP-15-03-KRIBB]
Genome editing took a dramatic turn with the development of the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated proteins (Cas) system. The CRISPR-Cas system is functionally divided into classes 1 and 2 according to the composition of the effector genes. Class 2 consists of a single effector nuclease, and routine practice of genome editing has been achieved by the development of the Class 2 CRISPR-Cas system, which includes the type II, V, and VI CRISPR-Cas systems. Types II and V can be used for DNA editing, while type VI is employed for RNA editing. CRISPR techniques induce both qualitative and quantitative alterations in gene expression via the double-stranded breakage (DSB) repair pathway, base editing, transposase-dependent DNA integration, and gene regulation using the CRISPR-dCas or type VI CRISPR system. Despite significant technical improvements, technical challenges should be further addressed, including insufficient indel and HDR efficiency, off-target activity, the large size of Cas, PAM restrictions, and immune responses. If sophisticatedly refined, CRISPR technology will harness the process of DNA rewriting, which has potential applications in therapeutics, diagnostics, and biotechnology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据